Monogram Technologies Shareholders Approve Zimmer Biomet Merger
The deal paves the way for the integration of Monogram's advanced surgical robotics, with a closing date set for early October 2025.
Shareholders of Monogram Technologies Inc. (MGRM) have given the green light for its acquisition by a wholly-owned subsidiary of Zimmer Biomet, a giant in the medical device industry. The merger, which is now tentatively scheduled to close before the market opens on October 7, 2025, marks a pivotal step in Zimmer Biomet's strategy to lead the rapidly advancing field of orthopedic robotics.
The transaction values Monogram at approximately $177 million, with Zimmer Biomet set to acquire all outstanding shares for an upfront payment of $4.04 per share in cash. In a move that signals confidence in Monogram's future pipeline, the also include a non-tradeable Contingent Value Right (CVR) that could entitle stockholders to an additional $12.37 per share based on the achievement of specific developmental and revenue milestones through 2030.
The acquisition is a significant strategic maneuver for Zimmer Biomet, aimed at bolstering its flagship ROSA® Robotics platform with Monogram's innovative semi-autonomous and fully autonomous surgical technologies. Monogram has been a pioneer in developing an AI-navigated total knee arthroplasty (TKA) robot, which received FDA 510(k) clearance in March 2025. Zimmer Biomet's acquisition positions it to become potentially the first company in orthopedics to offer a , a development that could redefine the standard of care in the sector.
was one of the final hurdles for the merger, which had already received unanimous approval from the boards of directors of both companies. Following the closing of the deal, Monogram will be delisted from the Nasdaq stock exchange and operate as a wholly-owned subsidiary of Zimmer Biomet. The integration is expected to be neutral to Zimmer Biomet's adjusted earnings per share through 2027, becoming accretive in 2028 and beyond, with the first commercial use of the new technology with Zimmer Biomet implants anticipated in early 2027.